BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 19327467)

  • 1. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
    Choi CW; Kang DH; Kim GH; Eum JS; Lee SM; Song GA; Kim DU; Kim ID; Cho M
    Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
    Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
    Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
    Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
    Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.
    Katsinelos P; Fasoulas K; Paroutoglou G; Chatzimavroudis G; Beltsis A; Terzoudis S; Katsinelos T; Dimou E; Zavos C; Kaltsa A; Kountouras J
    Endoscopy; 2012 Jan; 44(1):53-9. PubMed ID: 22198776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
    Kaffes AJ; Bourke MJ; Ding S; Alrubaie A; Kwan V; Williams SJ
    Gastrointest Endosc; 2006 Sep; 64(3):351-7. PubMed ID: 16923481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needle-knife sphincterotomy: factors predicting its use and the relationship with post-ERCP pancreatitis (with video).
    Bailey AA; Bourke MJ; Kaffes AJ; Byth K; Lee EY; Williams SJ
    Gastrointest Endosc; 2010 Feb; 71(2):266-71. PubMed ID: 20003969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of cannulation technique in ERCP: effects on technical success and post-ERCP pancreatitis.
    Bailey AA; Bourke MJ; Williams SJ; Walsh PR; Murray MA; Lee EY; Kwan V; Lynch PM
    Endoscopy; 2008 Apr; 40(4):296-301. PubMed ID: 18389448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
    Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
    Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP.
    Sotoudehmanesh R; Khatibian M; Kolahdoozan S; Ainechi S; Malboosbaf R; Nouraie M
    Am J Gastroenterol; 2007 May; 102(5):978-83. PubMed ID: 17355281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study.
    Testoni PA; Mariani A; Giussani A; Vailati C; Masci E; Macarri G; Ghezzo L; Familiari L; Giardullo N; Mutignani M; Lombardi G; Talamini G; Spadaccini A; Briglia R; Piazzi L;
    Am J Gastroenterol; 2010 Aug; 105(8):1753-61. PubMed ID: 20372116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
    Cheon YK; Cho KB; Watkins JL; McHenry L; Fogel EL; Sherman S; Schmidt S; Lazzell-Pannell L; Lehman GA
    Gastrointest Endosc; 2007 Dec; 66(6):1126-32. PubMed ID: 18061712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidewire cannulation reduces risk of post-ERCP pancreatitis and facilitates bile duct cannulation.
    Artifon EL; Sakai P; Cunha JE; Halwan B; Ishioka S; Kumar A
    Am J Gastroenterol; 2007 Oct; 102(10):2147-53. PubMed ID: 17581267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results.
    Saad AM; Fogel EL; McHenry L; Watkins JL; Sherman S; Lazzell-Pannell L; Lehman GA
    Gastrointest Endosc; 2008 Feb; 67(2):255-61. PubMed ID: 18028920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study.
    Kwanngern K; Tiyapattanaputi P; Wanitpukdeedecha M; Navicharern P
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S42-5. PubMed ID: 16623000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors.
    Christoforidis E; Goulimaris I; Kanellos I; Tsalis K; Demetriades C; Betsis D
    Endoscopy; 2002 Apr; 34(4):286-92. PubMed ID: 11932783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing post-ERCP pancreatitis: where are we?
    Testoni PA
    JOP; 2003 Jan; 4(1):22-32. PubMed ID: 12555013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.
    Yoo KS; Huh KR; Kim YJ; Kim KO; Park CH; Hahn T; Park SH; Kim JH; Park CK; Kwon YJ; Lehman GA
    Pancreas; 2011 Mar; 40(2):181-6. PubMed ID: 21206331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial.
    Romagnuolo J; Hilsden R; Sandha GS; Cole M; Bass S; May G; Love J; Bain VG; McKaigney J; Fedorak RN
    Clin Gastroenterol Hepatol; 2008 Apr; 6(4):465-71; quiz 371. PubMed ID: 18304883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.